




Lung Perfusion Solution

- Increasing the number of donor lungs available for transplantation



Opportunity:

Many patients die awaiting donor lungs due to a worldwide shortage of suitable organs. During conventional organ preservation and storage, donor lungs may become damaged due to ischaemia and hypothermia. To increase the number of donor lungs available for transplantation, ex vivo lung perfusion (EVLP) is now commonly used to recondition and assess lungs previously considered unsuitable. One of the main factors limiting the duration of EVPL is oedema formation, which prevents extending the period of reconditioning required to make “marginal” lungs suitable for transplantation. UCD has developed a lung preservation solution with a novel mechanism of action which results in a protective effect against oedema formation in transplanted lungs.

Applications:

Lung Transplantation: EVPL (*ex vivo* lung perfusion)

Key Features/Advantages:

UCD’s novel lung preservation solution is designed to:

- Extend lung survival in EVLP
- Improve preservation of vascular function
- Improve lung performance following reconditioning
- Increase viability of “marginal” organs, making them suitable for transplantation

Value Proposition:

Improves lung performance of lung transplants, increasing the number of donor lungs available for transplantation

Market:

Global *ex vivo* lung perfusion (EVPL) market

Lead Inventor:

Prof Paul McLoughlin, School of Medicine, Conway Institute, UCD

IP Status/Publication:

National filing in US, regional filing in Europe. Published as WO 2016/162536 A1



Contact:

Dr Ena Walsh
Case Manager
Knowledge Transfer
t: + 353 1 716 3706
e: ena.walsh@ucd.ie

FUNDERS:

